Preclinical studies with mouse or human cancer cells in vitro and in vivo have demonstrated anti‐tumoral efficacy of combining mTOR inhibitors with ICI such as PD‐1/PD‐L1 inhibitors and others [6, 7]. Here, MTOR is linked to cancer.